Pharmacokinetic Characterization of a Single 200 mg Dose of Doxycycline in Post-exposure Prophylaxis (PEP) of Sexually Transmitted Infections in Different Biological Compartments

Recruiting N/A Interventional Study
Post-exposure Prophylaxis Sexually Transmitted Diseases Doxycycline
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Male
Study type
Interventional
Purpose
Other
Participants needed
25 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Post-exposure prophylaxis (PEP) using doxycycline 200 mg within 24 hours of unprotected sexual intercourse to prevent sexually transmitted infections has demonstrated a reduction in the incidence of chlamydial and syphilis infections and syphilis infection by 70% and 73% in men who have sex with men (MSM) undergoing pre-exposure prophylaxis prophylaxis (PrEP) for HIV. Other studies are underway or…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult male patient * Men who have Sex with Men (MSM) on PrEP or HIV-infected patients * Patients who have not taken doxycycline for at least 3 months * No symptoms of bacterial STI infection (chlamydia, gonorrhea, Mycoplasma genitalium or syphilis). * Documented history of bac…
Contacts

Lauriane GOLDWIRT, Dr

+33142494325

lauriane.goldwirt@aphp.fr

CONTACT

Jérôme Lambert, Dr

+33142499742

jerome.lambert@u-paris.fr

CONTACT